ArticleEFSA journal. European Food Safety Authority2026
Knowledge mapping of risk mitigation measures against vector-borne diseases.
Article in EFSA journal. European Food Safety Authority, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Vector-borne diseases-knowledge maps.EFSA journal. European Food Safety Authority · 2026Article
- Potential entry pathways for 25 vector-borne disease agents.EFSA journal. European Food Safety Authority · 2026Article
- Knowledge mapping of risk mitigation measures against vector-borne diseases.EFSA journal. European Food Safety Authority · 2026Article
- Identification and mapping of potential and highly likely vectors for selected vector-borne diseases in the EU and neighbouring countries.EFSA journal. European Food Safety Authority · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A comprehensive synthesis of current evidence on surveillance, prevention and control measures for 25 selected vector-borne diseases (VBDs) affecting animals in the EU is presented here. The assessment integrates evidence from systematic literature reviews, modelling studies, field investigations and expert judgement. The aim is mapping the availability and effectiveness of risk mitigation measures (RMMs), including surveillance, movement restrictions, vaccination, culling, medicinal treatments, on-farm biosecurity and vector control. Of the 25 VBDs considered, 13 are listed under the EU Animal Health Law (AHL) and categorised according to disease control priorities, while 12 additional non-listed diseases were included based on vector presence and epidemiological relevance. Surveillance emerges as the most comprehensively documented mitigation category and is recognised as the cornerstone of VBD risk management. Evidence supports its critical role in early detection, situational awareness and timely response through integrated monitoring of hosts, vectors, pathogens and environmental drivers. Movement restrictions are supported by a moderate evidence base, primarily derived from modelling studies, indicating that they can reduce transmission under specific epidemiological conditions; however, their stand-alone effectiveness is difficult to quantify in real-world outbreaks. Vaccination shows high efficacy and effectiveness for several key VBDs, including African horse sickness virus, bluetongue virus, lumpy skin disease virus and Rift Valley fever virus, with substantial reductions in infection, morbidity and mortality. Evidence for culling is limited and highly disease-specific, and its effectiveness is generally contingent on the combination with other control measures. Medicinal treatments are limited to some groups of pathogens and demonstrate variable effectiveness, with emerging concerns regarding drug resistance. Biosecurity and vector control measures are supported by heterogeneous evidence, with chemical vector control showing robust entomological efficacy, but limited empirical data linking vector reduction to disease incidence. The report identifies key knowledge gaps and uncertainties across RMM categories and provides targeted recommendations for research to strengthen future VBD mitigation capacity in the EU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.